tIn 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Flu-darabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the completeresponse rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS wassignificantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stemcell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile andevidence of a benefit in a small series of CLL patients with adverse biologic features.
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
MUSOLINO, Caterina;
2014-01-01
Abstract
tIn 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Flu-darabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the completeresponse rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS wassignificantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stemcell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile andevidence of a benefit in a small series of CLL patients with adverse biologic features.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
